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fpa leaflet on the combined pill
John Guillebaud provides comment about fpa's new leaflet on the combined pill entitled Your Guide to the Combined Pill and 'Missed Pill' Guidance that relates to its content and development.
fpa is the leading sexual health charity in the UK, providing a national information service to the public. fpa helpline and information services respond to more than 100 000 enquiries annually and provide more than 10 million leaflets a year to support women's and men's information needs and enable them to make good, confident choices about contraception and other areas of sexual health.
All fpa leaflets contain, where possible, evidence-based information or agreed current practice and consensus opinion. It is vital that fpa information 'mirrors' evidence-based guidance to ensure that information is harmonised for both professionals and the public. All fpa leaflets are subject to a robust consultation process that involves input from a number of experts in the field, which includes the FFPRHC, to ensure medical accuracy. It also includes consumer testing of the leaflet format and content with the intended audience to ensure it is appropriate and accessible.
The medical information in this new leaflet is based on WHO Medical Eligibility Criteria for Contraceptive Use. 1 Information about what to do if women miss pills or start a packet late is based on WHO Selected Practice Recommendations for Contraceptive Use, 2 which has been endorsed by the FFPRHC. fpa's new leaflet on combined oral contraception and the Faculty advice on 'missed pills' were published simultaneously to ensure women and professionals received this new information at the same time.
John Guillebaud questions and disagrees with the new Faculty advice on 'missed pills': as such he takes issue with the new fpa leaflet, which contains the same information. Individual clinicians may disagree with guidelines and may choose to provide alternative advice to their clients, but they need to be clear why their advice is different from consensus practice and be prepared to defend it with women. fpa has the responsibility to ensure it provides information based on evidence or consensus opinion and to produce it in a way that is effective for consumers not professionals. fpa contraceptive leaflets are not product leaflets nor are they teaching tools for professionals: instead they are produced for women choosing and using contraception. Importantly, they provide 'back-up' information to support practitioners' verbal advice, but they are not intended to replace it.
In reality, women want to feel confident about using the pill, they want to know what to do if they miss pills, start a packet late, become ill, or take concomitant medicines that may affect pill efficacy. This new advice provides for the first time the possibility for consistent information to be given in a way that is understandable and easy to follow. We now all have a responsibility to promote this and ensure it is known about. To do this demands improved understanding and listening by professionals about the issues that worry women about oral contraception and the confusion that exists around taking it correctly.
Toni Belfield, BSc How can: Missed ONE or TWO pills -"She does not need any additional contraceptive protection" possibly apply if the two missed pills were at one side of the pill-free interval (PFI)?
Or, how can: Missed THREE or more pills -"She should also use condoms or abstain from sex until she has taken pills for 7 days in a row" possibly apply if she has already taken the "seven consecutive pills [which] are sufficient to inhibit ovulation" and has not missed the more than seven which are quoted above as being necessary to lose protection?
Are we alone in translating this as: It's OK to have a PFI of 9 days, don't worry about it, but it's not OK to have a 3-day break in the middle of the pack?
We know we're not alone: many people have asked us to explain it to them and we cannot.
We are all for simplifying things: "Field experience shows a need for simple, harmonised guidance". So, why complicate matters even further by giving two sets of rules for two sets of pills? Wouldn't it have been simpler to go with the lowest common denominator, however irrational.
And then there's the evidence. Several studies have looked at follicular development following extension of the PFI to 9 or 10 days and have found it to be significant; more so in 20 µg than in 30 or 35 µg ethinylestradiol formulations.
Mishell 2 quite categorically states that there is an increased risk of pregnancy if the PFI is prolonged to 9 days, quoting Creinin et al. 3 who found that extending the hormone-free interval from 7 to 9 days with two low-dose formulations resulted in some women having elevated circulating endogenous progesterone levels, providing evidence of luteal activity. These findings would support a reduction in the 7 day PFI rather than permitting any extension.
We would welcome further enlightenment. 
Missed pills
I am writing on behalf of GPs and nurses at Leeds Student Medical Practice -a practice serving the University here, and hence with 30 000+ patients very busy with contraceptive issues. We welcome your missed pills guidelines 1 and were hoping to use them as a definitive guide. However, we are confused.
The advice re three or more 30 µg pills or two or more 20 µg pills missed mentions using emergency contraception (EC) if necessary in the first week. It is not mentioned in the second or third week. Does this mean that EC is not required for up to seven pills missed in these weeks? (NB. The article states >7 pills missed cannot use missed-pill guidelines.) This would seem to make some sense on the basis that it takes >7 missed pills before ovulation may occur.
If that is the case, then why is the 7-day rule suggested for missed pills in these weeks?
Or should we be giving EC if unprotected sex has occurred and three or more 30 µg pills or two or more 20 µg pills have been missed in the second or third week, as is our current practice?
We would value your help and clarification please.
Debbie Smith, MRCGP 
